About OriCiro Genomics
OriCiro Genomics is a Healthcare company based in Tokyo (Japan) founded in 2018, and was acquired by Moderna in January 2023. Technologies for DNA synthesis and amplification are developed. OriCiro Genomics has raised $10.87 million across 4 funding rounds from investors including Moderna, Asahi Kasei and UT-EC Japan. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Genomics.
Company details
OriCiro Genomics was established in 2018 in Tokyo, Japan, within the biotechnology sector. Focus is placed on developing technologies for DNA synthesis and amplification. The OriCiro Cell-Free Cloning System is provided, consisting of the OriCiro Assembly Kit and OriCiro Amp Kit. Cell-free assembly and amplification of circular DNA molecules are facilitated through this system, supporting genomic research and applications. Operations are centered in Japan, with a domain at oriciro.com.
- Headquarters Tokyo, Japan
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website oriciro.com
- Social LinkedIn X
- Acquired by Moderna (Jan 2023)
Funding Insights of OriCiro Genomics
OriCiro Genomics has successfully raised a total of $10.87M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.87M
- Total Rounds 4
- First Round $3.58M
(Apr 2019)
- Investors Count 4
All 4 funding rounds of OriCiro Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
5 investors in total: 5 institutional.
Investors in OriCiro Genomics
OriCiro Genomics has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Moderna, Asahi Kasei and UT-EC Japan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and Early stage VC firm investing in Japan | ut-ec.co.jp | Tokyo, Japan | ||
| asahi-kasei.co.jp | ||||
| techv.co.jp | ||||
| jfc.go.jp | ||||
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | modernatx.com | Cambridge, United States |
Investor details for OriCiro Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OriCiro Genomics
6 people are tracked at OriCiro Genomics (2 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Nasir Bashiruddin | Chief Executive Officer | Leadership |
Shige Sasaki | COO and CBO 取締役 | Leadership |
Taro Mizuno | Senior Manager | Team |
Kei Sasahara | Business Management Dept. Manager | Team |
Makoto Shiraishi | Intellectual Property Manager | Team |
Keizo Fujimaki | Manager, QA/QC & Operation | Team |
Complete people profiles for OriCiro Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of OriCiro Genomics
4 dated milestones of OriCiro Genomics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded OriCiro Genomics is founded.
- Funding First funding round of $3.6M.
- Funding Latest funding round, Series B,.
- Exit Acquired by Moderna.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oriciro Genomics
Complete news archive for OriCiro Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OriCiro Genomics
OriCiro Genomics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
OriCiro Genomics is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
OriCiro Genomics is a funded company, having raised a total of $10.87M across 4 funding rounds to date. The company's 1st funding round was a Series A of $3.58M, raised on Apr 2019.
OriCiro Genomics was established in 2018 in Tokyo, Japan, within the biotechnology sector. Focus is placed on developing technologies for DNA synthesis and amplification. The OriCiro Cell-Free Cloning System is provided, consisting of the OriCiro Assembly Kit and OriCiro Amp Kit. Cell-free assembly and amplification of circular DNA molecules are facilitated through this system, supporting genomic research and applications. Operations are centered in Japan, with a domain at oriciro.com.
OriCiro Genomics has 5 investors. Key investors include Moderna, Asahi Kasei, UT-EC Japan, ITV, and JFC.
Yes. OriCiro Genomics was acquired by Moderna in January 2023.